ONCOGIN Project

GENERAL INFORMATION

 

Complex project title: “Multidisciplinary Consortium for Supporting Research Skills in Diagnosing, Treating and Identifying Predictive Factors of Malignant Gynecologic Disorders”

Project acronym: ONCOGIN

Project coordinator: Dr. Suciu Nicolae

Competition: “Complex projects completed in consortia CDI” (PCCI), PN III, Program 1, Subprogram 1.2.

Contracting Authority: Executive Unit for Financing Higher Education, Research, Development and Innovation (UEFISCDI)

Project code: PN-III-P1-1.2-PCCDI2017-0833

Contract number: 68PCCDI/2018

Project duration: 05.04.2018-30.09.2020

 

PARTNERS

Partner institutions:

Project coordinator: The Institute for Mother and Child Protection “Prof. Dr. Al Rusescu”(IMCP) Project Director:Prof. Dr. Nicolae Suciu

P1- Fundeni Clinical Institute

P2-Institute of Oncology Prof. Dr. Alexandru Trestoianu

P3-Carol Davila University of Medicine and Pharmacy, Bucharest

P4-Horia Hulubei National Institute of Physics and Nuclear Engineering (IFIN-HH)

 

OBJECTIVES

Aim: INSMC, having the role of project coordinator, together with the 4 partners, aims to discover and introduce new methods of diagnosis, treatment and prognosis in the field of oncoginecology by identifying revolutionary biomarkers.

The main objective of the project was to find new communication pathways by identifying new markers of angiogenesis and new immunological treatment targets in order to reduce / inhibit tumor progression.

 

The two sub-projects have in common research, development of models and innovative methods, creating human resources through the shared use of existing infrastructures. Development of personalized therapy to address new therapeutic targets that will be identified in ovarian cancer using new techniques such as NGS (Next Generation Sequencing) for BRCA 1 and BRCA 2 determination, microarray for miRNA and application of advanced bioanalytical tools. Based on analysis of immunohistochemistry, special imaging and genomics, the following are pursued:

  1.  formation of groups of patients;
  2.  elaboration of a working algorithm that identifies the patients who will develop chemoresistance;
  3.  identification of a back-up test using multigenic analyzes corroborated with imaging methods; drafting informed consent forms; elaboration of the patient evaluation sheet; standardized working procedures described below in the report.

 

Specific activities

Optimization of the workflow and methods of RNA extraction from paraffin samples, fresh frozen tissue, blood, in order to carry out the molecular biology experiments provided in the project.

Selection criteria for patients with peritoneal carcinomatosis in gynecological malignancies.

Development of conceptual models regarding the optimization of the culture methods of the peritoneum / ascites tumor cells.

Consolidation of the consortium and establishment of synergistic and complementary activities in the HIPEC study in peritoneal carcinomatosis.

Selection and inclusion of patients in the batch. - patients with peritoneal carcinomatosis candidates for cytoreduction and HIPEC. - patients with recurrence after initial surgical and chemotherapy treatment.

Obtaining biospecimens (tumor tissue, peritoneum and liquid biopsy / ascites + blood) from patients in whom cytoreduction and HIPEC were performed. Anatomical-histological characterization of tumor / peritumoral samples ".

Extraction of nucleic acids (RNA / DNA) from tissue samples / ascites / serum obtained

Preparation and preliminary testing of some radiotherapy devices for PET imaging in ovarian and breast cancers.

 

Identification of molecular predictors of  HYPERTHERMIC Intraperitoneal Chemotherapy (HIPEC) response and study of mechanisms involved in resistance to treatment in ovarian cancer

  • Patient selection and inclusion in the batch. - patients with peritoneal carcinomatosis who are candidates for cytoreduction and HIPEC. - patients with recurrence after the initial surgical and chemotherapy treatment.
  • Evaluation of BRCA1 / 2 mutation in patients selected by targeted sequencing techniques.
  • Obtaining biospecimens (tumor tissue, peritoneum and liquid / ascites + blood biopsy) from patients in whom cytoreduction and HIPEC were performed. Anatomical-histological characterization of tumor / peritumoral samples.
  • Extraction of nucleic acids (RNA / DNA) from tissue samples / ascites / serum obtained.
  • Generation of miRNA of interest by microarray analysis of the samples obtained before and after performing HIPEC.
  • Selection, by bioinformatic analysis of genes of interest (mRNA) - targets modeled by miRNA of interest. Highlighting the signaling pathways specific to the response to HIPEC.
  • QRT-PCR validation of a miRNA panel obtained after bioinformatics analysis.
  • In vitro determination of the expression of HER2 receptors in ovarian cancers with radiotransactors on standardized and cultured cell cultures.